Genovate Biotechnology Co., Ltd. (TPEX:4130)
27.85
+0.50 (1.83%)
At close: Jul 9, 2026
Genovate Biotechnology Revenue
Genovate Biotechnology had revenue of 110.38M TWD in the quarter ending March 31, 2026, a decrease of -15.93%. This brings the company's revenue in the last twelve months to 471.48M, down -6.23% year-over-year. In the year 2025, Genovate Biotechnology had annual revenue of 492.41M, down -3.61%.
Revenue (ttm)
471.48M
Revenue Growth
-6.23%
P/S Ratio
8.08
Revenue / Employee
2.44M
Employees
193
Market Cap
3.81B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 492.41M | -18.45M | -3.61% |
| Dec 31, 2024 | 510.86M | -17.66M | -3.34% |
| Dec 31, 2023 | 528.51M | 89.75M | 20.46% |
| Dec 31, 2022 | 438.76M | 4.51M | 1.04% |
| Dec 31, 2021 | 434.25M | -38.47M | -8.14% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Apex Biotechnology | 1.91B |
| SYN-TECH Chem. & Pharm. | 1.26B |
| Chunghwa Chemical Synthesis & Biotech | 973.15M |
| Sagittarius Life Science | 392.26M |
| BioGend Therapeutics | 229.81M |
| Intech Biopharm | 117.49M |
| Formosa Pharmaceuticals | 54.32M |
| OBI Pharma | 49.68M |